Protagenic Therapeutics (PTIX) AI Stock Analysis

• Market Cap: $2.92M
• Dividend Yield: N/A
• Average Volume (3M): 10.50M
• Price to Earnings (P/E): ―
• Beta (1Y): -1.62
• Revenue Growth: N/A
• EPS Growth: -40.51%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 77
• Industry: Biotechnology
• EPS (TTM): -1.13
• Shares Outstanding: 7,525,681
• 10 Day Avg. Volume: 20,292,830
• 30 Day Avg. Volume: 10,496,787
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -2.60
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Protagenic Therapeutics faces significant financial difficulties, with no revenue and persistent losses. Technical indicators suggest weak market momentum, and the company's valuation is unattractive due to negative earnings. These factors collectively result in a low overall stock score, reflecting substantial risks and challenges.

Protagenic Therapeutics Business Overview & Revenue Model

Company Description

Protagenic Therapeutics, Inc. (PTIX) is a biotechnology company operating in the pharmaceutical sector, with a focus on developing therapies for various central nervous system (CNS) disorders. The company's core product line includes proprietary neuropeptide-based therapeutics aimed at treating conditions such as depression, anxiety, post-traumatic stress disorder (PTSD), and other stress-related disorders. Protagenic Therapeutics leverages its intellectual property portfolio to advance its drug candidates through preclinical and clinical development stages.

How the Company Makes Money

Protagenic Therapeutics primarily makes money through the development and commercialization of its neuropeptide-based therapeutics. The company seeks to generate revenue by advancing its drug candidates through clinical trials, obtaining regulatory approvals, and ultimately licensing or partnering these therapeutics with larger pharmaceutical companies for distribution and marketing. Key revenue streams include milestone payments from strategic partnerships, licensing agreements, and eventually, sales of approved therapeutics. The company's ability to secure funding through equity offerings, grants, and collaborations also plays a crucial role in supporting its research and development efforts.

Protagenic Therapeutics Financial Statement Overview

Summary

Protagenic Therapeutics faces substantial financial challenges with persistent losses and cash outflows. While its debt-free position reduces leverage risks, the declining equity and high operating costs necessitate strategic financial management to improve its financial health and sustainability.

Income Statement

Protagenic Therapeutics has consistently shown negative profitability with a net loss over multiple periods. The TTM (Trailing-Twelve-Months) data shows some revenue generation, but the gross and net profit margins are negative, indicating high costs relative to revenue. The EBIT and EBITDA margins are also significantly negative, suggesting operational inefficiencies.

Balance Sheet

The company's balance sheet shows a relatively low leverage with zero total debt, which is a positive indicator. However, the stockholders' equity has significantly declined, leading to a low equity ratio. The return on equity is not meaningful due to negative net income, indicating poor returns on equity capital.

Cash Flow

The cash flow statement reveals negative free cash flow and operating cash flow, reflecting cash burn in operations. Although there is an increase in investing cash flow, it is overshadowed by significant operating cash outflows. This raises concerns about sustainability without external funding.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
28.34K	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-23.42K	-28.22K	-30.00	0.00	-286.00	-339.00
	EBIT
-5.27M	-4.53M	-3.56M	-4.14M	-2.55M	-2.09M
	EBITDA
-5.56M	-4.50M	-3.42M	-4.14M	-2.55M	-2.09M
	Net Income Common Stockholders
-5.65M	-5.00M	-3.60M	-4.99M	-2.79M	-1.77M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.10M	4.06M	7.98M	10.37M	671.09K	798.62K
	Total Assets
3.16M	4.32M	8.04M	11.06M	879.25K	842.27K
	Total Debt
0.00	0.00	344.23K	318.43K	1.37M	279.37K
	Net Debt
-3.10M	-1.29M	129.04K	-222.74K	702.71K	-519.25K
	Total Liabilities
684.86K	655.25K	1.12M	1.12M	2.03M	1.48M
	Stockholders Equity
2.48M	3.67M	6.92M	9.94M	-1.15M	-634.37K
Cash Flow		Free Cash Flow
-4.64M	-3.85M	-2.00M	-2.80M	-1.35M	-487.99K
	Operating Cash Flow
-4.54M	-3.70M	-1.99M	-2.80M	-1.35M	-487.99K
	Investing Cash Flow
5.08M	4.78M	1.60M	-9.91M	0.00	250.00K
	Financing Cash Flow
361.50K	0.00	0.00	12.58M	1.22M	670.00K

Protagenic Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.39
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PTIX, the sentiment is Positive. The current price of 0.39 is above the 20-day moving average (MA) of 0.27, above the 50-day MA of 0.30, and below the 200-day MA of 0.56, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 45.70 is Neutral, neither overbought nor oversold. The STOCH value of 21.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PTIX.

Protagenic Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACAD	76 Outperform	$2.57B	11.31	38.89%	―	31.85%	―
AVXL	62 Neutral	$696.68M	―	-37.72%	―	―	-3.08%
AXSM	51 Neutral	$4.82B	―	-231.63%	―	42.53%	-15.29%
Sector *	48 Neutral	$6.36B	1.14	-49.00%	2.63%	17.14%	1.39%
ANVS	38 Underperform	$25.53M	―	-3159.09%	―	―	68.75%
BCLI	30 Underperform	$7.50M	―	234.90%	―	―	62.35%
PTIX	27 Underperform	$2.92M	―	-236.06%	―	―	-40.51%

Protagenic Therapeutics Corporate Events

Protagenic Therapeutics Reprices Stock Options at Annual Meeting

On February 21, 2025, Protagenic Therapeutics Inc. held its 2024 Annual Meeting of Stockholders, where stockholders approved a proposal to reprice certain outstanding stock options under the company’s 2006 and 2016 Equity Incentive Plans. The Board of Directors subsequently repriced these options to an exercise price of $0.2655 per share, aligning with the closing price of the company’s common stock on that date, potentially impacting the company’s financial strategy and stakeholder interests.